GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (NAS:SYRS) » Definitions » Cyclically Adjusted PB Ratio

Syros Pharmaceuticals (Syros Pharmaceuticals) Cyclically Adjusted PB Ratio : 2.20 (As of May. 01, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-01), Syros Pharmaceuticals's current share price is $5.29. Syros Pharmaceuticals's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 was $2.40. Syros Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 2.20.

The historical rank and industry rank for Syros Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

SYRS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.89   Med: 2.76   Max: 3.23
Current: 2.24

During the past 10 years, Syros Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 3.23. The lowest was 1.89. And the median was 2.76.

SYRS's Cyclically Adjusted PB Ratio is ranked worse than
58.23% of 644 companies
in the Biotechnology industry
Industry Median: 1.74 vs SYRS: 2.24

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Syros Pharmaceuticals's adjusted book value per share data of for the fiscal year that ended in Dec23 was $0.630. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.40 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Syros Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Syros Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 3.25

Syros Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 3.25

Competitive Comparison of Syros Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Syros Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syros Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Syros Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Syros Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=5.29/2.4
=2.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syros Pharmaceuticals's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Syros Pharmaceuticals's adjusted Book Value per Share data for the fiscal year that ended in Dec23 was:

Adj_Book=Book Value per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=0.63/129.4194*129.4194
=0.630

Current CPI (Dec23) = 129.4194.

Syros Pharmaceuticals Annual Data

Book Value per Share CPI Adj_Book
201412 -87.790 99.070 -114.684
201512 -21.074 99.792 -27.331
201612 34.473 101.863 43.799
201712 24.722 104.011 30.761
201812 23.274 105.998 28.417
201912 18.259 108.420 21.795
202012 16.106 109.897 18.967
202112 13.740 117.630 15.117
202212 6.304 125.222 6.515
202312 0.630 129.419 0.630

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Syros Pharmaceuticals  (NAS:SYRS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Syros Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Syros Pharmaceuticals (Syros Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is mainly involved in the segments of pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The Company operates only in the United States.
Executives
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
David Roth officer: Chief Medical Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Eric R Olson officer: Chief Scientific Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson director ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh director C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Jason Haas officer: Chief Financial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley officer: Chief Commercial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Kristin Stephens officer: Chief Development Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Richard A Young director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn officer: Chief Business Officer C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
Arch Venture Fund Vii, L.p. 10 percent owner 8755 W HIGGINS, SUITE 1025, Chicago IL 60631
Alice Tsang Shaw director MASSACHUSETTS GENERAL HOSPITAL, 55 FRUIT ST., #148, BOSTON MA 02114

Syros Pharmaceuticals (Syros Pharmaceuticals) Headlines

From GuruFocus

Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference

By Business Wire Business Wire 06-08-2023